(Q26998884)

language of work or name

1 reference

October 2014

1 reference

American Journal of Hematology

published in

1 reference

volume

89

1 reference

issue

10

1 reference

page(s)

999-1009

1 reference

Approach to the treatment of multiple myeloma: a clash of philosophies.

cites work

1 reference

21 January 2018

Cancer statistics, 2014

1 reference

Incidence of multiple myeloma in Olmsted County, Minnesota: Trend over 6 decades

21 January 2018

1 reference

Patterns of monoclonal gammopathy of undetermined significance and multiple myeloma in various ethnic/racial groups: support for genetic factors in pathogenesis

21 January 2018

1 reference

Review of 1027 patients with newly diagnosed multiple myeloma

21 January 2018

1 reference

Pathogenesis of myeloma bone disease

21 January 2018

1 reference

Comparison of modern and conventional imaging techniques in establishing multiple myeloma-related bone disease: a systematic review

21 January 2018

1 reference

Incidence of extramedullary disease in patients with multiple myeloma in the era of novel therapy, and the activity of pomalidomide on extramedullary myeloma

21 January 2018

1 reference

Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study

21 January 2018

1 reference

A monoclonal gammopathy precedes multiple myeloma in most patients

21 January 2018

1 reference

A long-term study of prognosis in monoclonal gammopathy of undetermined significance.

21 January 2018

1 reference

Prevalence of monoclonal gammopathy of undetermined significance

21 January 2018

1 reference

Prevalence and risk of progression of light-chain monoclonal gammopathy of undetermined significance: a retrospective population-based cohort study

21 January 2018

1 reference

Racial disparities in the prevalence of monoclonal gammopathies: a population-based study of 12,482 persons from the National Health and Nutritional Examination Survey

21 January 2018

1 reference

Incidence of monoclonal gammopathy of undetermined significance and estimation of duration before first clinical recognition

21 January 2018

1 reference

Impact of primary molecular cytogenetic abnormalities and risk of progression in smoldering multiple myeloma

21 January 2018

1 reference

Progression in smoldering myeloma is independently determined by the chromosomal abnormalities del(17p), t(4;14), gain 1q, hyperdiploidy, and tumor load

21 January 2018

1 reference

Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma

21 January 2018

1 reference

Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group

21 January 2018

1 reference

Prognostic validation of the international classification of immunoglobulin M gammopathies: a survival advantage for patients with immunoglobulin M monoclonal gammopathy of undetermined significance?

21 January 2018

1 reference

Immunoglobulin M monoclonal gammopathies of undetermined significance and indolent Waldenstrom's macroglobulinemia recognize the same determinants of evolution into symptomatic lymphoid disorders: proposal for a common prognostic scoring system.

21 January 2018

1 reference

Clinicopathological definition of Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia

21 January 2018

1 reference

Solitary plasmacytoma of bone and extramedullary plasmacytoma

21 January 2018

1 reference

Monoclonal gammopathy of undetermined significance, Waldenström macroglobulinemia, AL amyloidosis, and related plasma cell disorders: diagnosis and treatment

21 January 2018

1 reference

POEMS syndrome: definitions and long-term outcome

21 January 2018

1 reference

21 January 2018

1 reference

Diagnosis of smoldering multiple myeloma

21 January 2018

1 reference

Elimination of the need for urine studies in the screening algorithm for monoclonal gammopathies by using serum immunofixation and free light chain assays

21 January 2018

1 reference

Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines

21 January 2018

1 reference

The molecular characterization and clinical management of multiple myeloma in the post-genome era.

21 January 2018

1 reference

Myeloma bone disease: pathogenetic mechanisms and clinical assessment.

21 January 2018

1 reference

International myeloma working group consensus statement and guidelines regarding the current role of imaging techniques in the diagnosis and monitoring of multiple Myeloma

21 January 2018

1 reference

International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders

21 January 2018

1 reference

International uniform response criteria for multiple myeloma.

21 January 2018

1 reference

Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1.

21 January 2018

1 reference

A clinical staging system for multiple myeloma correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival

21 January 2018

1 reference

International staging system for multiple myeloma

21 January 2018

1 reference

Is the International Staging System superior to the Durie-Salmon staging system? A comparison in multiple myeloma patients undergoing autologous transplant

21 January 2018

1 reference

International Myeloma Working Group molecular classification of multiple myeloma: spotlight review.

21 January 2018

1 reference

Trisomies in multiple myeloma: impact on survival in patients with high-risk cytogenetics

21 January 2018

1 reference

A phase III randomized trial of thalidomide plus zoledronic acid versus zoledronic acid alone in patients with asymptomatic multiple myeloma

21 January 2018

1 reference

Lenalidomide plus dexamethasone for high-risk smoldering multiple myeloma

21 January 2018

1 reference

Serum free light chain ratio as a biomarker for high-risk smoldering multiple myeloma

21 January 2018

1 reference

Extensive bone marrow infiltration and abnormal free light chain ratio identifies patients with asymptomatic myeloma at high risk for progression to symptomatic disease

21 January 2018

1 reference

Improved survival in multiple myeloma and the impact of novel therapies

21 January 2018

1 reference

Antitumor activity of thalidomide in refractory multiple myeloma

21 January 2018

1 reference

Bortezomib or high-dose dexamethasone for relapsed multiple myeloma

21 January 2018

1 reference

Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma

21 January 2018

1 reference

A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma

21 January 2018

1 reference

Proteasome inhibition as a novel therapeutic target in human cancer.

21 January 2018

1 reference

Acquisition of a multidrug-resistant phenotype with a proteasome inhibitor in multiple myeloma

21 January 2018

1 reference

Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma

21 January 2018

1 reference

Identification of a primary target of thalidomide teratogenicity

21 January 2018

1 reference

Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide.

21 January 2018

1 reference

21 January 2018

1 reference

Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group

21 January 2018

1 reference

Multicenter, randomized, double-blind, placebo-controlled study of thalidomide plus dexamethasone compared with dexamethasone as initial therapy for newly diagnosed multiple myeloma

21 January 2018

1 reference

Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial

21 January 2018

1 reference

Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial

21 January 2018

1 reference

Efficacy of melphalan and prednisone plus thalidomide in patients older than 75 years with newly diagnosed multiple myeloma: IFM 01/01 trial.

21 January 2018

1 reference

Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: a randomized controlled trial

21 January 2018

1 reference

Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma

21 January 2018

1 reference

Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised p

21 January 2018

1 reference

Cyclophosphamide, bortezomib and dexamethasone induction for newly diagnosed multiple myeloma: high response rates in a phase II clinical trial.

21 January 2018

1 reference

Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma.

21 January 2018

1 reference

Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma

21 January 2018

1 reference

A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma

21 January 2018

1 reference

Evolution of carfilzomib dose and schedule in patients with multiple myeloma: a historical overview

21 January 2018

1 reference

Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study

21 January 2018

1 reference

Total Therapy 3 for multiple myeloma: prognostic implications of cumulative dosing and premature discontinuation of VTD maintenance components, bortezomib, thalidomide, and dexamethasone, relevant to all phases of therapy

21 January 2018

1 reference

Bortezomib plus melphalan and prednisone compared with melphalan and prednisone in previously untreated multiple myeloma: updated follow-up and impact of subsequent therapy in the phase III VISTA trial

21 January 2018

1 reference

Treatment of myeloma: cure vs control

21 January 2018

1 reference

Benefit of complete response in multiple myeloma limited to high-risk subgroup identified by gene expression profiling

21 January 2018

1 reference

Impact of lenalidomide therapy on stem cell mobilization and engraftment post-peripheral blood stem cell transplantation in patients with newly diagnosed myeloma

21 January 2018

1 reference

Mobilization in myeloma revisited: IMWG consensus perspectives on stem cell collection following initial therapy with thalidomide-, lenalidomide-, or bortezomib-containing regimens

21 January 2018

1 reference

International myeloma working group (IMWG) consensus statement and guidelines regarding the current status of stem cell collection and high-dose therapy for multiple myeloma and the role of plerixafor (AMD 3100).

21 January 2018

1 reference

Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma

21 January 2018

1 reference

Superior results of Total Therapy 3 (2003-33) in gene expression profiling-defined low-risk multiple myeloma confirmed in subsequent trial 2006-66 with VRD maintenance

21 January 2018

1 reference

Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study

21 January 2018

1 reference

Stem cell collection in patients with de novo multiple myeloma treated with the combination of bortezomib and dexamethasone before autologous stem cell transplantation according to IFM 2005-01 trial.

21 January 2018

1 reference

A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma

21 January 2018

1 reference

Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial

21 January 2018

1 reference

Melphalan and prednisone plus thalidomide or placebo in elderly patients with multiple myeloma

21 January 2018

1 reference

Phase III study of the value of thalidomide added to melphalan plus prednisone in elderly patients with newly diagnosed multiple myeloma: the HOVON 49 Study

21 January 2018

1 reference

Melphalan and prednisone versus melphalan, prednisone and thalidomide for elderly and/or transplant ineligible patients with multiple myeloma: a meta-analysis

21 January 2018

1 reference

Thalidomide for previously untreated elderly patients with multiple myeloma: meta-analysis of 1685 individual patient data from 6 randomized clinical trials

21 January 2018

1 reference

21 January 2018

1 reference

Thalidomide-dexamethasone compared with melphalan-prednisolone in elderly patients with multiple myeloma

21 January 2018

1 reference

High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma

21 January 2018

1 reference

Management of multiple myeloma: a systematic review and critical appraisal of published studies

21 January 2018

1 reference

Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup Trial S9321.

21 January 2018

1 reference

High-dose therapy intensification compared with continued standard chemotherapy in multiple myeloma patients responding to the initial chemotherapy: long-term results from a prospective randomized trial from the Spanish cooperative group PETHEMA.

21 January 2018

1 reference

Single versus double autologous stem-cell transplantation for multiple myeloma.

21 January 2018

1 reference

Consolidation therapy with low-dose thalidomide and prednisolone prolongs the survival of multiple myeloma patients undergoing a single autologous stem-cell transplantation procedure

21 January 2018

1 reference

Lenalidomide after stem-cell transplantation for multiple myeloma

21 January 2018

1 reference

Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65/ GMMG-HD4 trial.

21 January 2018

1 reference

Clinical course of patients with relapsed multiple myeloma

21 January 2018

1 reference

Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study

21 January 2018

1 reference

Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma

21 January 2018

1 reference

Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America

21 January 2018

1 reference

VTD combination therapy with bortezomib-thalidomide-dexamethasone is highly effective in advanced and refractory multiple myeloma

21 January 2018

1 reference

Multicenter, phase I, dose-escalation trial of lenalidomide plus bortezomib for relapsed and relapsed/refractory multiple myeloma

21 January 2018

1 reference

Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression

21 January 2018

1 reference

An open-label, single-arm, phase 2 (PX-171-004) study of single-agent carfilzomib in bortezomib-naive patients with relapsed and/or refractory multiple myeloma

21 January 2018

1 reference

Pomalidomide (CC4047) plus low-dose dexamethasone as therapy for relapsed multiple myeloma

21 January 2018

1 reference

Pomalidomide (CC4047) plus low dose dexamethasone (Pom/dex) is active and well tolerated in lenalidomide refractory multiple myeloma (MM).

21 January 2018

1 reference

Pomalidomide plus low-dose dexamethasone in myeloma refractory to both bortezomib and lenalidomide: comparison of 2 dosing strategies in dual-refractory disease

21 January 2018

1 reference

Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial

21 January 2018

1 reference

Prospective, randomized study of single compared with double autologous stem-cell transplantation for multiple myeloma: Bologna 96 clinical study

21 January 2018

1 reference

Clinical Course and Prognosis of Smoldering (Asymptomatic) Multiple Myeloma

21 January 2018

1 reference

21 January 2018

1 reference

Aspirin, Warfarin, or Enoxaparin Thromboprophylaxis in Patients With Multiple Myeloma Treated With Thalidomide: A Phase III, Open-Label, Randomized Trial

21 January 2018

1 reference

Aspirin or enoxaparin thromboprophylaxis for patients with newly diagnosed multiple myeloma treated with lenalidomide

21 January 2018

1 reference

Lenalidomide Maintenance after Stem-Cell Transplantation for Multiple Myeloma

21 January 2018

1 reference